Related Experiment Videos
8-MOP plasma levels in PUVA problem cases with psoriasis
Abstract:
8-MOP plasma levels of psoriatic patients poorly responsive to PUVA treatment (PUVA problem cases) (N = 14) and of psoriatic patients with adequate response to photochemotherapy (N = 7) were measured for 8 h after oral ingestion of 0.6-0.8 mg/kg body weight, using a gas chromatographic method. We investigated whether there are any differences in the course of the plasma kinetics between the two groups. Problem patients showed significantly lower 8-MOP plasma levels than the control group. Furthermore, the 8-MOP plasma levels increased more rapidly in the control group than in these problem patients. Deviations in time of the maximum 8-MOP plasma levels from the expected 2 h peak could be observed in 50% of the problem cases compared to only 14% of the control patients. There is no correlation between the dose and the 8-MOP plasma level achieved in the two groups, i.e. higher doses do not result in high levels. In individual cases there is not always a correlation between the plasma maximum of 8-MOP at the time of UV-A irradiation and the response to treatment. Adjustment of the UV-A irradiation to coincide with the maximum plasma levels led to an improvement in therapeutic results for three problem patients.
Insights
Psoriatic patients with poor response to PUVA therapy had lower 8-methoxypsoralen (8-MOP) plasma levels and delayed absorption compared to those with adequate responses. Optimizing UV-A irradiation timing improved outcomes for some patients.
Area of Science:
- Dermatology
- Pharmacokinetics
- Photochemotherapy
Background:
- Psoriasis is a chronic inflammatory skin condition.
- Photochemotherapy, specifically PUVA (psoralen plus UVA light), is a common treatment for psoriasis.
- Variability in patient response to PUVA suggests underlying pharmacokinetic differences.
Purpose of the Study:
- To compare 8-methoxypsoralen (8-MOP) plasma pharmacokinetics between psoriatic patients with poor and adequate responses to PUVA treatment.
- To investigate potential correlations between 8-MOP plasma levels, absorption kinetics, and therapeutic outcomes.
- To explore if adjusting UV-A irradiation timing based on 8-MOP plasma peaks improves treatment efficacy.
Main Methods:
- Oral administration of 8-MOP (0.6-0.8 mg/kg) to psoriatic patients (N=14 poor responders, N=7 adequate responders).
- Measurement of 8-MOP plasma levels over 8 hours using gas chromatography.
- Analysis of plasma kinetics, including peak levels and time to peak, in relation to treatment response.
Main Results:
- Poor responders exhibited significantly lower 8-MOP plasma levels compared to adequate responders.
- The rate of 8-MOP plasma increase was slower in poor responders.
- Fifty percent of poor responders showed deviations in the time to maximum 8-MOP plasma levels, versus 14% of controls.
- No dose-response correlation was observed for 8-MOP plasma levels.
- Adjusting UV-A irradiation to 8-MOP plasma peaks improved outcomes in three poor responders.
Conclusions:
- Lower and delayed 8-MOP plasma levels may contribute to poor PUVA treatment response in some psoriatic patients.
- Individualized UV-A irradiation timing, synchronized with 8-MOP plasma peaks, shows potential for improving therapeutic results.
- Further research into pharmacokinetic variability can optimize photochemotherapy protocols for psoriasis.